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SUMMARY
In September 2006, the 7-valent pneumococcal conjugate vaccine (PCV7) was added to the
UK immunization programme. We aimed to evaluate the impact of PCV7 on the incidence of
all-cause community-acquired pneumonia (CAP) in children. A prospective survey was
undertaken in 2008–2009 at 11 hospitals in North East England of children aged 0–16 years with
radiologically confirmed pneumonia. Data were compared to those from a similar survey
undertaken in the same hospitals in 2001–2002. A total of 542 children were enrolled, of which
74% were aged<5 years. PCV7 uptake was 90.7%. The incidence of pneumonia was 11.8/10 000
[95% confidence interval (CI) 10.9–12.9], and the hospitalization rate was 9.9/10 000 (95% CI
9.0–10.9). Compared to 2001, there was a 19% (95% CI 8–29) reduction in the rate of CAP in
those aged<5 years, and in those<2 years a 33.1% (95% CI 20–45) reduction in the incidence
of CAP and 38.1% (95% CI 24–50) reduction in hospitalization rates. However, for those
unvaccinated agedo5 years, there was no difference in the incidence of CAP and hospitalization
rate between both surveys. Since 2001, the overall reduction in incidence was 17.7% (95% CI
8–26) and for hospitalization 18.5% (95% CI 8–28). For the<5 years age group there was a
lower incidence of CAP in PCV7-vaccinated children (25.2/10 000, 95% CI 22.6–28.2) than in
those that were not vaccinated (37.4/10 000, 95% CI 29.2–47.1). In conclusion, PCV7 has reduced
both incidence and rate of hospitalization of pneumonia in children, particularly in the<2 years
age group.
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INTRODUCTION
Community-acquired pneumonia (CAP) is a common
childhood illness [1]. It causes about 20% of global
childhood mortality, mostly in resource-poor coun-
tries [2, 3]. Streptococcus pneumoniae is the leading
bacterial cause of pneumonia in young children [4].
In the UK, pneumococcal infection was identified in
nearly 10% of CAP in children [5, 6]. This is likely to
be an underestimation of the true burden of pneumo-
coccal disease, given the relative imprecision of
microbiological diagnosis of pneumonia in children [1].
In September 2006, the 7-valent pneumococcal
conjugate vaccine (PCV7) including antigen for sero-
types 4, 6B, 9V, 14, 18C, 19F, and 23F was added
to the UK immunization programme. The vaccine
schedule is three doses administered at ages 2, 4 and
13 months. When introduced, those aged>1 year and
f1 year received one and two doses, respectively
as part of a catch-up programme for children aged
<2 years. Subsequently this was replaced by PCV13
from April 2010, which also includes antigen for the
additional serotypes 1, 3, 5, 6A, 7F, and 19A.
The efficacy of pneumococcal conjugate vaccines in
preventing radiological pneumonia has been shown
to be up to 37% in randomized controlled trials
[7–11]. However, prospective epidemiological studies
are valuable in establishing the impact of vaccines
in populations outside trial settings [12, 13]. The
incidence of childhood CAP seen in hospitals in
North East England was evaluated prospectively in
2001–2002 [14]. At that time the incidence of child-
hood pneumonia was 14.4/10 000 (95% CI 13.4–15.4)
and 33.8/10 000 (95% CI 31.1–36.7) for those aged
<5 years [14]. This survey, which commenced in
2008, provides an opportunity to evaluate the impact
of the introduction of PCV7 on the incidence of
childhood pneumonia using prospective clinical data
in a defined and previously studied population.
METHODS
Study design and participants
This was a prospective survey involving 11 hospital
sites in North East England (excluding Cumbria).
It was conducted from August 2008 to July 2009,
covering the same months as the survey in 2001–2002.
The hospital configuration changed slightly from the
previous survey in 2001, with a reduction in the
number of hospitals treating children from 13 to 11.
However, the geographical area and population
served by these hospitals were the same as in 2001 as
were the methods of enrolment criteria and case
ascertainment [14]. In the UK, children are assessed
by a General Practitioner in primary care or by an
Emergency Room team and then referred to a hospital-
based paediatrician if secondary care is required.
Eligibility criteria were children aged 0–16 years,
who presented with clinical and radiological features
of pneumonia and were seen in hospital by a paedia-
trician. Data on chest radiographs were collated from
local radiologists’ reports and findings were grouped
according to a modified version of the WHO criteria
[15, 16]. Radiological reports were grouped into
five categories (lobar, patchy consolidation, perihilar
infiltrates, other infiltrates/abnormalities, normal).
The other infiltrates/abnormalities included reports
of increased bronchovascular markings, peribronchial
thickening, bronchial wall thickening, or peribronchial
cuffing and were analysed as pneumonia. The modi-
fication of including a further category (other
infiltrates/abnormalities) is in line with the extended
definitions of pneumonia used by Enwere et al. [17]
in their study of the epidemiology of pneumonia
in the Gambian PCV9 trial. Exclusion criteria in-
cluded being resident outside North East England,
clinically diagnosed bronchiolitis, hospitalization for
any reason in the preceding 3 weeks, or a chest
radiograph reported as normal.
A favourable ethical opinion was obtained from the
regional Newcastle and North Tyneside Research
Ethics Committee. Caldicott approvals were granted
from all collaborating sites.
Case ascertainment and data validation
Children were identified prospectively by local paedi-
atric teams who completed a proforma containing
data on demographics, clinical findings, management
and outcomes. Enrolment data were cross-checked to
ensure complete ascertainment by reviewing ward
admission diaries for children admitted with respir-
atory symptoms (eight sites), or by obtaining hospital
coding data on pneumonia admissions (three sites).
Case-notes and electronic records were reviewed to
confirm the diagnosis, and to collect any missing data.
Pneumococcal immunization history was obtained for
each child from parents, and where available it was
cross-checked with the child’s parent-held health re-
cords. If there was uncertainty about the immuniz-
ation history, general practice surgeries were contacted
and practice records of vaccines given were checked.
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Classification of disease severity and social class
Disease severity was determined using modified cri-
teria from the British Thoracic Society (BTS) man-
agement guidelines for pneumonia [18]. The symptom
of dyspnoea was excluded as the definition was
deemed subjective, particularly in preschool-age chil-
dren [19]. Any of the following led to the classification
of ‘severe disease’ : respiratory rate >70 or >50 for
f1- or>1-year-olds, respectively ; oxygen saturation
<93%; oxygen therapy; nasogastric feeds; intra-
venous fluid infusion; septicaemia; empyema; high
dependency or intensive care admission. ‘Mild dis-
ease ’ included immediate discharge home or hospital
stay<3 days and no oxygen therapy; no nasogastric
feeds and no intravenous fluid infusion. Children
with none of the above were classified as having
‘moderate disease ’. Parental occupation information
was incomplete, therefore socioeconomic class and
the measure of deprivation were derived for each
child based on the Index of Multiple Deprivation
score (IMD) for the parental postcode of residence
(The English Index of Deprivation 2007, Office for
National Statistics).
Statistical analysis
Incidence rates were established by age and sex
using the population estimates for the North East
Strategic Health Authority area from the UK Office
of National Statistics for 2009. There were 458 500
children aged<16 years, of which 146 200 were aged
<5 years [20]. Confidence intervals (CIs) of incidence
rates were calculated assuming a Poisson distribution
and using the EpiTools package in R statistical soft-
ware version 2.14.0 (The R Foundation for Statistical
Computing, Austria). Univariate and multivariate
logistic regression was used to establish risk factors
for severe compared to mild/moderate CAP. Fisher’s
exact test was used to compare differences in count
data between 2001 and 2009 for disease severity.
RESULTS
A total of 582 children were initially identified; 40
were excluded (34 had a normal chest radiograph,
six lived outside the North East), leaving 542 eligible
for inclusion (58% males). There were no deaths.
Overall, 98% received antibiotics and 84% were ad-
mitted to hospital. Lobar consolidation was reported
in 30%, and pleural effusion was present on 9.6% of
the chest radiographs. Four hundred children aged
<5 years were included, of these, 320 were vaccinated
with PCV7, 33 were eligible for the vaccine but had
not received it, for nine vaccination status was un-
known and 38 were ineligible for the vaccine on age
grounds. One child who was ineligible on age grounds
had received the vaccine. Hence, the PCV7 uptake
was 90.7% in the eligible children in the survey.
The annual incidence of pneumonia was 11.8/
10 000 children aged <16 years (95% CI 10.9–12.9),
with 27.4/10 000 (95% CI 24.8–30.2) in the<5 years
age group. This compared to 14.4/10 000 (95% CI
13.4–15.4) and 33.8/10 000 (95% CI 31.1–36.7), re-
spectively in 2001 [14]. The hospitalization rate was
9.9/10 000 (95% CI 9.0–10.9) for all, and 22.4/10 000
(95% CI 20.1–25.0) for those aged <5 years. This
was lower than the 2001 rates ; 12.2/10 000 (95% CI
11.3–13.2) and 28.7/10 000 (95% CI 26.2–31.4), re-
spectively. By calculation of the incidence rate ratio,
the overall reduction in incidence between 2001 and
2009 was 17.7% (95% CI 8–26) and the reduction in
hospitalization rate was 18.5% (95% CI 8–28). The
reduction in pneumonia in the <5 years age group
was 19% (95% CI 8–29%). Table 1 compares data
between the 2001 and 2009 surveys.
There was a significantly lower incidence of pneu-
monia in children aged <5 years vaccinated with
PCV7 (25.2/10 000, 95% CI 22.6–28.2) compared to
those that were unvaccinated (37.4/10 000, 95% CI
29.2–47.1) [odds ratio (OR) 4.5, 95% CI 3.5–5.9].
However, there was no significant difference in the
incidence of severe disease between the vaccinated
children (13.0/10 000, 95% CI 11.1–15.1) and those
unvaccinated in the<5 years age group (22.6/10 000,
95% CI 16.4–30.5) (OR 0.7, 95% CI 0.4–1.2). Of
those aged<2 years, there was a significant reduction
of 33.1% (95% CI 20–45) in the incidence of pneu-
monia from 49.9/10 000 (95% CI 44.1–56.4) in 2001
to 33.5/10 000 (95% CI 28.9–38.4) in 2009, whereas
the reduction in hospitalization was 38.1% (95% CI
24–50) between 2001 and 2009 (Table 1). Reduction in
both the incidence of pneumonia and hospitalization
between 2001 and 2009 was also observed in the
2.0–4.9 years age group by 23.1% (95% CI 7–36) and
29.8% (95% CI 14–43), respectively. In theo5 years
group, there was no difference in the incidence of
pneumonia between 2001 and 2009 (incidence rate
ratio 0.85, 95% CI 0.7–1.2), nor the hospitalization
rate between both studies (incidence rate ratio 0.9,
95% CI 0.7–1.2).
Most cases (n=363, 67%) occurred during the
winter and spring seasons. Table 2 summarizes the
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incidence rates of CAP by age group for disease
severity and chest radiographic findings. Overall,
males had higher rates of CAP for different categories
of disease severity. In both males and females the
rates in children aged <5 years were sixfold higher
than those aged o5 years. Patchy changes were the
most common chest radiographic finding particularly
in the <5 years age group. Lobar pneumonia was
seen in a quarter of children aged<5 years, compared
to about 15% in 2001. There was an overall signifi-
cant increase in the incidence of lobar pneumonia
from 2.8/10 000 (95% CI 2.3–3.3) in 2001 to
3.5/10 000 (95% CI 3.0–4.1) in 2009 (OR 1.3, 95% CI
1.01–1.6). No significant risk factors for severe
Table 1. Comparison of rates of pneumonia and hospitalization between 2001
and 2009 data per 10 000 children
Variables
2001 survey
IR (95% CI)
2009 survey
IR (95% CI)
Reduction
% (95% CI)
Overall
Pneumonia 14.4 (13.4–15.4) 11.8 (10.9–12.9) 17.7 (8 to 26)
Hospitalization 12.2 (11.3–13.2) 9.9 (9.0–10.9) 18.5 (8 to 28)
<2 years
Pneumonia 49.9 (44.1–56.4) 33.5 (28.9–38.4) 33.1 (20 to 45)
Hospitalization 45.6 (40.1–51.8) 28.2 (24.1–32.8) 38.1 (24 to 50)
2.0–4.9 years
Pneumonia 30.7 (27.1–34.6) 23.6 (20.4–27.1) 23.1 (7 to 36)
Hospitalization 27.5 (24.1–31.3) 19.3 (16.5–22.5) 29.8 (14 to 43)
<5 years
Pneumonia 33.8 (31.1–36.7) 27.4 (24.8–30.2) 19.1 (8 to 29)
Hospitalization 28.7 (26.2–31.4) 22.4 (20.1–25.0) 21.9 (10 to 32)
o5 years
Pneumonia 5.3 (4.6–6.1) 4.5 (3.8–5.4) 14.7 (–7 to 32)*
Hospitalization 4.5 (3.8–5.2) 4.1 (3.4–4.8) 9.4 (–15 to 29)*
IR, Incidence rate ; CI, confidence interval.
* Negative numbers denote an estimate of an increase in incidence.
Table 2. Incidence rates of pneumonia per 10 000 children (August 2008–July 2009)
Variables
<5 years (n=400) o5 years (n=142) Overall (n=542)
n (%) IR (95% CI) n (%) IR (95% CI) n (%) IR (95% CI)
Male 227 (56.8) 15.5 (13.6–17.7) 86 (60.6) 2.8 (2.2–3.4) 313 (57.7) 6.8 (6.1–7.6)
Female 173 (43.2) 11.8 (10.1–13.7) 56 (39.4) 1.8 (1.4–2.3) 229 (42.3) 5.0 (4.4–5.7)
Disease severity
Mild 147 (36.8) 10.1 (8.5–11.8) 56 (39.4) 1.8 (1.4–2.3) 203 (37.5) 4.4 (3.9–5.1)
Moderate 40 (10.0) 2.7 (1.9–3.7) 16 (11.3) 0.5 (0.3–0.8) 56 (10.3) 1.2 (0.9–1.6)
Severe 213 (53.2) 14.6 (12.7–16.7) 70 (49.3) 2.2 (1.8–2.8) 283 (52.2) 6.2 (5.5–6.9)
Chest radiographic findings
Patchy 227 (56.8) 15.5 (13.6–17.7) 69 (48.6) 2.2 (1.7–2.8) 296 (54.6) 6.5 (5.7–7.2)
Lobar 99 (24.8) 6.8 (5.5–8.2) 63 (44.4) 2.0 (1.6–2.6) 162 (29.9) 3.5 (3.0–4.1)
Perihilar 61 (15.2) 4.2 (3.2–5.4) 6 (4.2) 0.2 (0.1–0.4) 67 (12.4) 1.5 (1.1–1.9)
Other infiltrates 13 (3.2) 0.9 (0.5–1.5) 4 (2.8) 0.1 (0.03–0.3) 17 (3.1) 0.4 (0.2–0.6)
Social class (IMD score)
1st quantile (2.97–14.46) 101 (25.2) 6.9 (5.6–8.4) 29 (20.4) 0.9 (0.6–1.3) 130 (24.0) 2.8 (2.4–3.4)
2nd quantile (14.47–25.33) 92 (23.0) 6.3 (5.1–7.7) 36 (25.3) 1.2 (0.8–1.6) 128 (23.6) 2.8 (2.3–3.3)
3rd quantile (25.34–42.44) 102 (25.5) 6.9 (5.7–8.5) 43 (30.3) 1.4 (0.9–1.9) 145 (26.8) 3.2 (2.7–3.7)
4th quantile (42.45–78.53) 105 (26.3) 7.2 (5.9–8.7) 34 (23.9) 1.1 (0.8–1.5) 139 (25.6) 3.0 (2.6–3.6)
IR, Incidence rate ; CI, confidence interval ; IMD, index of multiple deprivation.
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pneumonia were identified with univariate or multi-
variate logistic regression. These included age, gender,
socioeconomic status, prematurity, parental smoking
and asthma (Table 3).
DISCUSSION
This is the first prospective survey in the UK to
evaluate the effect of PCV7 on the incidence of child-
hood CAP. We report an 18% reduction in both the
incidence of CAP presenting to hospital and hospi-
talization between 2001 and 2009. There was a lower
incidence of pneumonia in PCV7-vaccinated children
aged <5 years than those unvaccinated. Rates of
pneumonia and likelihood of hospital admission were
highest in the <5 years age group, consistent with
previous studies [14, 21].
There were no significant risk factors for severe
pneumonia in this survey, although extreme prema-
turity was a risk factor for severe disease in 2001 [14].
This may reflect changes in neonatal care in the
intervening period. However, in a recent study our
region had the highest bronchopulmonary dysplasia
rate in Europe, suggesting that the relationship may
be complex [22]. It was surprising that parental
smoking was not a risk factor for severe pneumonia,
given that we had a relative excess of smoking in our
cohort (37%) compared to the national average rate
of 21% for adults [1]. Although parental smoking was
not a significant risk factor for severe disease, where
parents were smokers 58% of their children had
severe disease.
Comparison with other studies
The reduction in both incidence of pneumonia and
hospitalization rate in this survey is comparable with
a previous study in England [23], which reported a
19% decrease between 2006 and 2008 in childhood
pneumonia using hospital episodes statistics (HES)
data. The reduction in the rate of hospitalization was
more than that reported in Canada of 13% in those
aged <5 years following the routine introduction of
PCV7 [24]. The disease incidence is also close to the
estimates of other studies of PCV11 in the Philippines
[25] and PCV7 in the USA [9] that reported decreases
in all-cause pneumonia by about 22%. It is, however,
lower than the 25% reduction against radiological
pneumonia reported in randomized controlled trial of
PCV9 in South Africa [7] and 30% in the USA [26].
Table 3. Univariate risk factors of severe versus mild/moderate pneumonia
Characteristics n (%) OR (95% CI) P value
Age group
<5 years 400 (73.8) 1.7 (0.8–1.6) 0.418
o5 years 142 (26.2) 1.0 —
Sex
Female 229 (42.3) 1.0 —
Male 313 (57.7) 1.2 (0.8–1.6) 0.427
Social class (IMD score)
1st quantile (2.97–14.46) 130 (24.0) 1.0 —
2nd quantile (14.47–25.33) 128 (23.6) 1.1 (0.7–1.9) 0.612
3rd quantile (25.34–42.44) 145 (26.8) 0.9 (0.6–1.5) 0.755
4th quantile (42.45–78.53) 139 (25.6) 1.1 (0.7–1.7) 0.780
Gestation (weeks)
24–28 7 (1.3) 5.8 (0.7–48.4) 0.105
29–32 13 (2.4) 1.5 (0.5–4.8) 0.452
33–36 25 (4.6) 1.7 (0.7–3.9) 0.206
o37 497 (91.7) 1.0 —
Parental smoking
No 247 (62.8) 1.0 —
Yes 146 (37.2) 1.3 (0.8–1.9) 0.253
Asthma
No 501 (92.4) 1.0 —
Yes 41 (7.6) 1.6 (0.9–3.2) 0.139
OR, Odds ratio ; CI, confidence interval ; IMD, index of multiple deprivation.
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This may be a reflection of the differences in
pneumococcal disease between populations or in
adherence and vaccine usage in our population
compared to the trial settings. As our survey used a
standard and comparable radiological definition of
pneumonia it should not reflect differences in disease
ascertainment between the studies.
Interestingly, the major reduction in pneumonia
admissions (38%) was observed in those aged <2
years. This is similar to the finding from the USA of
about 40% [27], but higher than that observed (15%)
during the PCV9 trial in The Gambia [8]. The marked
reduction of 33% in disease incidence in the<2 years
age group is also comparable to the reported inci-
dence reduction of up to 37% from the pneumococcal
conjugate vaccination trials and pooled review data
[8, 10, 11]. We observed a greater decrease (30%) in
the admission rate in those aged 2–4 years compared
to the 17% found by Grijalva et al. [27].
This survey has demonstrated a reduction in all-
cause pneumonia. Previous estimates have suggested
around 10% of childhood pneumonia is attributable
to S. pneumoniae in the UK [5, 6]. Given the decline
in pneumonia and assuming the absence of other
changes in disease or admission procedures, it seems
likely that 10% is a significant underestimation of
the true burden of pneumococcal-related childhood
pneumonia in the UK [1, 28]. It is only recently that
any studies have been able to describe the relative
contributions of different pneumococcal serotypes in
paediatric pneumonia [29], and these have not yet
been established in UK children. At the moment the
pneumococcal serotype distribution in childhood
pneumonia in the UK has only been inferred from
surveillance of invasive pneumococcal disease by the
Health Protection Agency and studies from other
countries. Thus, the potential reduction in pneumo-
coccal childhood pneumonia in the UK provided by
PCV7 is not known with certainty. This survey is a
significant step towards reducing that uncertainty.
Future studies are needed to carefully evaluate the
epidemiological and health economic impacts of the
new generation of conjugate vaccines.
Strengths and limitations
The strengths of this survey include the use of a multi-
centre large-scale approach, well-validated disease
definition and a previously studied population allow-
ing accurate historical comparisons. Its significant
limitation is that while the introduction of PCV7 is
the major change between the two surveys, the eco-
logical nature of the survey means that the decrease in
incidence cannot be causally attributed to PCV7 alone
[30, 31]. Further potentially relevant factors include
natural variations in disease incidence, other public
health interventions such as anti-smoking campaigns
[32, 33], variation in national and local health policies,
changes in admission criteria and threshold for
radiological investigation, and the implementation of
national guidelines for the management of CAP in
children by the BTS in 2002 [18]. While we cannot rule
out these factors using our methodology, we feel it is
unlikely that any of these factors would have reduced
the incidence of pneumonia to the degree observed.
Furthermore, we speculate that these factors would
alter the overall incidence rate regardless of age
group. The fact that we found no significant difference
in the incidence of pneumonia in the o5 years age
group, by definition non-vaccine recipients, therefore
increases the likelihood that the observed changes
were attributable to PCV7.
It could be speculated that changes in the incidence
of viral disease or vaccination may have contributed
to the observed differences in the rates of pneumonia,
although this is unlikely given that neither age group
(and specifically the<2 years age group) are routinely
vaccinated against respiratory viral disease. We did
not collect specific data on influenza vaccination
status but believe that the overwhelming majority of
enrolled children were unvaccinated. It has also
been hypothesized that a considerable proportion
of viral pneumonia may in fact have co-infection
with bacterial pathogens including S. pneumoniae as
shown by Michelow et al. [34] which could potentially
ameliorate the effect of variations in the incidence of
seasonal influenza or other viral infections.
The addition of a further group of ‘other infiltrates/
abnormalities ’ chest radiographic features to the
WHO definition of radiological pneumonia could
have overestimated the incidence of pneumonia
within our population. However, the number of such
individuals was low and represented only 3% of all
cases of pneumonia within our survey. We would
therefore suggest that this should not have signifi-
cantly influenced our findings, given the magnitude of
the changes we report. In contrast to the observed
substantial reduction in the incidence of lobar
pneumonia following the conjugate vaccination pro-
gramme in Canada [24], we reported increased lobar
findings. This could be attributed to either the relative
implication of S. pneumoniae in the aetiology of
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pneumonia in children or due to the recognized
variation in the interpretation of paediatric chest
radiographs [35], which in our survey were reported
by local radiologists at each site.
In conclusion, our findings suggest that PCV7 was
effective in reducing by 18% both the incidence of
childhood pneumonia seen in hospital and rates of
hospitalization in one population within the UK.
In particular, these reductions were more marked, by
nearly a third, in the<2 years age group.
ACKNOWLEDGEMENTS
We are grateful to the support of the paediatric staff in
the following hospitals : Queen Elizabeth Gateshead,
James Cook Middlesbrough, North Tyneside, South
Tyneside, Sunderland Royal, North Tees, North
Durham, Darlington Memorial, Freeman Newcastle,
Newcastle General, and Royal Victoria Infirmary.
This survey was supported by an unrestricted grant
from Pfizer (formerly Wyeth Vaccines UK) (no.
0887X1-4479). The sponsor had no role in the survey
design, and data collection, analysis or interpretation.
DECLARATION OF INTEREST
J.E.C. and D.A.S received unconditional research
support from Pfizer.
REFERENCES
1. Harris M, et al. British Thoracic Society guidelines for
the management of community acquired pneumonia
in children: update 2011. Thorax 2011; 66 (Suppl. 2) :
ii1-23.
2. Bryce J, et al. WHO estimates of the causes of death in
children. Lancet 2005; 365 : 1147–1152.
3. Rudan I, et al. Epidemiology and etiology of childhood
pneumonia. Bulletin of the World Health Organization
2008; 86 : 408–416.
4. Greenwood B. The epidemiology of pneumococcal
infection in children in the developing world. Philo-
sophical Transactions of the Royal Society of London,
Series B: Biological Sciences 1999; 354 : 777–785.
5. Clements H, et al. Rationalised prescribing for
community acquired pneumonia : a closed loop audit.
Archives of Disease in Childhood 2000; 83 : 320–324.
6. Drummond P, et al. Community acquired pneumo-
nia – a prospective UK study. Archives of Disease in
Childhood 2000; 83 : 408–412.
7. Klugman KP, et al. A trial of a 9-valent pneumococcal
conjugate vaccine in children with and those without
HIV infection. New England Journal of Medicine 2003;
349 : 1341–1348.
8. Cutts FT, et al. Efficacy of nine-valent pneumococcal
conjugate vaccine against pneumonia and invasive
pneumococcal disease in The Gambia : randomised,
double-blind, placebo-controlled trial. Lancet 2005;
365 : 1139–1146.
9. Black SB, et al. Effectiveness of heptavalent pneumo-
coccal conjugate vaccine in children younger than five
years of age for prevention of pneumonia. Pediatric
Infectious Disease Journal 2002; 21 : 810–815.
10. Lucero MG, et al. Pneumococcal conjugate vaccines for
preventing vaccine-type invasive pneumococcal disease
and X-ray defined pneumonia in children less than two
years of age. Cochrane Database of Systematic Reviews
2009; Issue 4. Art. No. CD004977.
11. Pavia M, et al. Efficacy of pneumococcal vaccination
in children younger than 24 months : a meta-analysis.
Pediatrics 2009; 123 : e1103–1110.
12. Orenstein WA, Bernier RH, Hinman AR. Assessing
vaccine efficacy in the field. Further observations.
Epidemiologic Reviews 1988; 10 : 212–241.
13. Victora CG,Habicht JP, Bryce J.Evidence-based public
health : moving beyond randomized trials. American
Journal of Public Health 2004; 94 : 400–405.
14. Clark JE, et al. Epidemiology of community-acquired
pneumonia in children seen in hospital. Epidemiology
and Infection 2007; 135 : 262–269.
15. Cherian T, et al. Standardized interpretation of
paediatric chest radiographs for the diagnosis of pneu-
monia in epidemiological studies. Bulletin of the World
Health Organization 2005; 83 : 353–359.
16. World Health Organization Pneumonia Vaccine Trial
Investigators Group. Standardization of interpretation
of chest radiographs for the diagnosis of pneumonia in
children. Geneva, WHO 2001; WHO/V&B/01.35.
17. Enwere G, et al. Epidemiology and clinical features of
pneumonia according to radiographic findings in
Gambian children. Tropical Medicine and International
Health 2007; 12 : 1377–1385.
18. British Thoracic Society. Guidelines for the manage-
ment of community acquired pneumonia in childhood.
Thorax 2002; 57 (Suppl. 1) : i1–24.
19. American Thoracic Society. Dyspnea. Mechanisms,
assessment, and management : a consensus statement.
American Journal of Respiratory and Critical Care
Medicine 1999; 159 : 321–340.
20. Office for National Statistics (ONS). Population esti-
mates for UK, England and Wales, Scotland and
Northern Ireland: mid year population estimates, 2009
(http://www.statistics.gov.uk/statbase/product.asp?vlnk=
15106). Accessed February 2012.
21. Jokinen C, et al. Incidence of community-acquired
pneumonia in the population of four municipalities
in eastern Finland. American Journal of Epidemiology
1993; 137 : 977–988.
22. Gortner L, et al. Rates of bronchopulmonary dysplasia
in very preterm neonates in Europe: results from the
MOSAIC cohort. Neonatology 2011; 99 : 112–117.
23. Koshy E, et al. Impact of the seven-valent pneumo-
coccal conjugate vaccination (PCV7) programme on
childhood hospital admissions for bacterial pneumonia
PCV7 and incidence of pneumonia 1703
and empyema in England: national time-trends study,
1997–2008. Thorax 2010; 65 : 770–774.
24. DeWals P, et al. Pneumonia after implementation of the
pneumococcal conjugate vaccine program in the prov-
ince of Quebec, Canada. Pediatric Infectious Disease
Journal 2008; 27 : 963–968.
25. Lucero MG, et al. Efficacy of an 11-valent pneumo-
coccal conjugate vaccine against radiologically con-
firmed pneumonia among children less than 2 years
of age in the Philippines : a randomized, double-blind,
placebo-controlled trial. Pediatric Infectious Disease
Journal 2009; 28 : 455–462.
26. Hansen J, et al. Effectiveness of heptavalent pneumo-
coccal conjugate vaccine in children younger than
5 years of age for prevention of pneumonia : updated
analysis using World Health Organization standardized
interpretation of chest radiographs. Pediatric Infectious
Disease Journal 2006; 25 : 779–781.
27. Grijalva CG, et al. Decline in pneumonia admissions
after routine childhood immunisation with pneumo-
coccal conjugate vaccine in the USA: a time-series
analysis. Lancet 2007; 369 : 1179–1186.
28. Madhi SA, Klugman KP. A role for Streptococcus
pneumoniae in virus-associated pneumonia. Nature
Medicine 2004; 10 : 811–813.
29. Resti M, et al. Community-acquired bacteremic pneu-
mococcal pneumonia in children: diagnosis and sero-
typing by real-time polymerase chain reaction using
blood samples. Clinical Infectious Diseases 2010; 51 :
1042–1049.
30. Hausdorff WP, Feikin DR, Klugman KP. Epidemio-
logical differences among pneumococcal serotypes.
Lancet Infectious Diseases 2005; 5 : 83–93.
31. van der Poll T, Opal SM. Pathogenesis, treatment, and
prevention of pneumococcal pneumonia. Lancet 2009;
374 : 1543–1556.
32. Garmendia J, Morey P, Bengoechea JA. Impact of
cigarette smoke exposure on host-bacterial pathogen
interactions. European Respiratory Journal 2012; 39 :
467–477.
33. Hill SC, Liang L. Smoking in the home and children’s
health. Tobacco Control 2008; 17 : 32–37.
34. Michelow IC, et al. Epidemiology and clinical
characteristics of community-acquired pneumonia
in hospitalized children. Pediatrics 2004 ; 113 : 701–
707.
35. Neuman MI, et al. Variability in the interpretation
of chest radiographs for the diagnosis of pneumonia
in children. Journal of Hospital Medicine 2012; 7 :
294–298.
1704 M. A. Elemraid and others
